All News

Through EVAPORATE, we've been able to show at 18 months that patients taking icosapent ethyl (Vascepa) have less plaque and that there is some atherosclerosis regression, marking mechanisms of benefit for these patients, said Matthew Budoff, MD, professor of medicine at the David Geffen School of Medicine at UCLA and investigator at The Lundquist Institute.

This week, the top managed care news included HHS defending a CDC change limiting COVID-19 testing for asymptomatic people; an inside look at the Facing Metastatic Breast Cancer Together campaign; a conversation with Dr Kashyap Patel on his new book.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo